Skip to main
PCVX

Vaxcyte (PCVX) Stock Forecast & Price Target

Vaxcyte (PCVX) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 75%
Buy 0%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Vaxcyte is expected to experience an overall increase in market demand for their vaccine candidates as the ACIP expands the universal adult vaccination age to over 50 years old, and their developing products, such as VAX-31 and VAX-24, show promising results. The company's strong pipeline, including their potentially superior and novel vaccine candidates, along with their use of advanced technology such as the XpressCF cell-free protein synthesis platform, position them for success in the potential $10B+ pneumococcal vaccine market. Furthermore, Vaxcyte has a strong balance sheet with a cash balance of $2.67B, providing a cash runway through multiple critical high-impact catalysts and de-risking events. However, there is a risk of potential regulatory changes that could impose additional burdens on the company, and profitability is not anticipated for several years due to the long development timelines and significant financial resources required for vaccine development. Overall, Vaxcyte seems well-positioned for future growth and success in the vaccine market.

Bears say

Vaxcyte is a clinical-stage vaccine company with a strong product pipeline, but their success is not guaranteed. The company currently has one vaccine candidate, VAX-31, in phase 3 clinical trials with promising data compared to competitors. However, there are risks associated with vaccine development and commercialization, and Vaxcyte will need to differentiate itself and build a commercial infrastructure to compete successfully with established players. Furthermore, changes in vaccination guidelines from organizations like the CDC could limit the company's commercial potential. Additionally, the company's financials show negative revenue from collaboration and other sources, asset impairment charges, and foreign exchange losses, which may further affect the company's performance. Overall, due to the significant challenges and uncertainties in the vaccine industry and the company's financial condition, the outlook for Vaxcyte's stock is negative.

Vaxcyte (PCVX) has been analyzed by 4 analysts, with a consensus rating of Buy. 75% of analysts recommend a Strong Buy, 0% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vaxcyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vaxcyte (PCVX) Forecast

Analysts have given Vaxcyte (PCVX) a Buy based on their latest research and market trends.

According to 4 analysts, Vaxcyte (PCVX) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $88.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $88.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vaxcyte (PCVX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.